Omacetaxine Mepesuccinate

FDA granted accelerated approval to omacetaxine mepesuccinate, (SYNRIBO for Injection, for subcutaneous use, Teva Pharmaceutical Industries Ltd.), for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). October 26, 2012.

 

More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm325990.htm



İletişim Adresi
info@losemilenfomamiyelom.org
  LÖSEMİ LENFOMA MİYELOM HASTALARI VE ARAŞTIRMA EĞİTİM BİRLİĞİ DERNEĞİ
Hoşdere Caddesi No: 198/5 Çankaya Ankara • www.losemilenfomamiyelom.org


28 Mayıs Dünya Kan Kanseri Günü
www.worldbloodcancerday.org

Web Tasarım: AdaNET